Milestone Pharmaceuticals Inc. (MIST) Stock Price & Analysis
Milestone Pharmaceuticals Inc. (MIST) closed at USD 0.79 on Thursday, October 15, 2026, up 0.84% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.79; the Oct 15, 2026 session ranged USD 0.75–0.8 on volume of 1,034,335 shares. Market capitalization is $98.91M, with a 52-week range of USD 0.71–3.06 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MIST.md
Key facts (MIST)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (7 analysts), mean target USD 5.86 (range 2–8).
- Total return with dividends: 1Y -59.6% vs S&P 500 +18.1%; 5Y -86.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.21, revenue estimate $1.1M.
Analysts (MIST)
Consensus Buy (mean 2.00 on a 1–5 scale), 7 analysts; mean target USD 5.86 (low 2, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-03 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-08-20 | Cantor Fitzgerald | Initiated | Overweight | $3 |
Total return (dividends reinvested) (MIST)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -59.6% | -86.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -59.8% | -33.0% |
| Volatility (annualized) | 73.8% | 86.1% |
| Max drawdown | -75.9% (Dec 2025→Oct 2026) | -92.7% (Oct 2022→Mar 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 0.79 |
|---|---|
| Change | ▲ 0.84% (up) |
| Previous Close | USD 0.79 |
| Open | USD 0.79 |
| Day Range | USD 0.75 – 0.8 |
| 52-Week Range | USD 0.71 – 3.06 |
| Volume | 1,034,335 shares |
| Market Cap | $98.91M |
| Exchange | NMS |
Technical Analysis (MIST)
Nexqual's technical model rates MIST "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 38.89 (neutral) |
| vs SMA50 | Below (USD 0.99) |
| MACD | -0.06 (negative) |
Analyst Ratings (MIST)
Wall Street analysts rate MIST "Buy" based on 7 analysts, with a mean price target of USD 5.86 (range USD 2–8), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 5.86 |
| High Target | USD 8 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 6 / 1 / 0 |
Earnings (MIST)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.21 |
| Revenue Estimate | $1.14M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.21 vs est -0.19 ▼ miss |
| 2026-03-31 | USD -0.2 vs est 0.19 ▼ miss |
| 2025-12-31 | USD -0.15 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.12 vs est -0.17 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (MIST)
| Total Revenue | $2.34M |
|---|---|
| Gross Margin | +98.04% |
| Operating Margin | -4584.97% |
| Profit Margin | +0.00% |
| ROE | -35522.62% |
| Debt / Equity | 7.79 |
| Current Ratio | 8.13 |
| Total Cash | $170.61M |
| Total Debt | $141.83M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (MIST)
Nexqual rates Milestone Pharmaceuticals Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $171M cash vs $142M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$61M (TTM) |
| Efficiency | Critical — ROE -35523%, ROA -42.8% |
Ownership (MIST)
| Insider Ownership | +0.70% |
|---|---|
| Institutional Ownership | +51.50% |
| Shares Outstanding | 124.50M |
| Float | 106.47M |
| Short % of Float | +15.38% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (MIST)
Milestone Pharmaceuticals Inc. is led by Joseph G. Oliveto (age 57), CEO, President & Executive Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO, President & Executive Director | Joseph G. Oliveto (age 57) |
|---|---|
| CFO & Executive VP of Corporate Development | Amit Hasija (age 52) |
| Chief Operating Officer | Jeffrey Nelson (age 44) |
| Vice President of Marketing | Roshan Girglani |
| Vice President of Sales | Jeff Moore |
Major Backers & Investors (MIST)
Notable institutional backers of Milestone Pharmaceuticals Inc. include Pavaki Capital Management LLC, RTW Investments LP, Propel Bio Management, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pavaki Capital Management LLC | 7.28% |
| RTW Investments LP | 6.29% |
| Propel Bio Management, LLC | 5.97% |
| Point72 Asset Management, L.P. | 4.35% |
| Simplify Asset Management, Inc. | 2.69% |
| Simplify Exchange Traded Funds-Simplify Propel Opportunities ETF | 2.69% |
| Millennium Management | 2.52% |
| Two Sigma Investments, LP | 1.64% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt